Real-world utilization and initial experience with aflibercept-ayyh (PAVBLU(R)) for retinal disorders in United States retina practices: A descriptive retrospective analysis
This retrospective real-world analysis of 1,000 eyes treated with the aflibercept biosimilar aflibercept-ayyh (PAVBLU) in US retina practices demonstrated stable visual acuity in previously treated patients, improved vision in treatment-naive patients, and a safety profile consistent with the reference drug, supporting its use as an effective alternative for retinal disorders.